Clinical Trials Browser

Breast Neoplasms × talazoparib × Sarcoma × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Clinical Trials

I-SPY

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors